BUZZ-Outset Medical rises after FDA clears upgraded dialysis system** Shares of medical device maker Outset Medical OM.O rise 8% to $5.30 premarket
** Co says the U.S. FDA cleared its next-generation dialysis system, Tablo, which has added reliability features
** Adds that Tablo's upgraded cybersecurity meets the FDA's latest standards
** Tablo is used for hemodialysis — a treatment that filters waste from the blood when kidneys fail
** Co says hardware and software updates are aimed at cutting maintenance needs and improving durability in hospitals
** Shipments of the new system to begin in Q2 2026; existing users can upgrade
** Shares fell ~78% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.